fda drug shortage list semaglutide What's New in Obesity Treatment? is semaglutide on the shortage

Market Share Projections Novo Nordisk itself forecasts that oral weight-loss drugs will capture more than one-third of the total GLP-1 market by 2030

Cost and Accessibility As a newer medication, tirzepatide may be more expensive than semaglutide in some regions

Is bloating worse after certain meal sizes

Improvements in Metabolic Health Didnt Last Weight wasnt the only thing affected after treatment stopped

and by prior HF (NYHA Class IIII, yes/no).39 The HRs favoured liraglutide versus placebo in all subgroups, apart from the subgroups at lowest CV risk in the former two analyses.37, 38, 39 The interaction of CV risk status at baseline on the treatment effect of liraglutide was not significant in any analysis, suggesting consistent CV effects across clinically relevant subgroups.37, 38 These findings may seem inconsistent with a prespecified subgroup analysis of LEADER, in which a significant interaction of treatment effect on MACE was observed in those aged 50 years with established CVD or CKD versus those aged 60 years with risk factors for CVD.2 However, considering the broad 95% CI in the CV risk factor only subgroup (0.86, 1.67), further study is warranted

13 While GLP-1 agonist-induced weight loss can decrease mechanical load through the musculoskeletal system and improve aspects of physical function, the resulting negative effects on tendons, impaired muscle function, and joint degradation can persist after a healthy weight has been achieved